Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.

Prevalence of neurocognitive impairment in HIV-1 infected patients is reported to be high. Whether this is a result of active HIV-related neurodegeneration is unclear. We examined axonal injury in HIV-1 patients by measuring the light subunit of neurofilament protein (NFL) in CSF with a novel, sensi...

Full description

Bibliographic Details
Main Authors: Jan Jessen Krut, Tomas Mellberg, Richard W Price, Lars Hagberg, Dietmar Fuchs, Lars Rosengren, Staffan Nilsson, Henrik Zetterberg, Magnus Gisslén
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3921217?pdf=render
_version_ 1819198448625254400
author Jan Jessen Krut
Tomas Mellberg
Richard W Price
Lars Hagberg
Dietmar Fuchs
Lars Rosengren
Staffan Nilsson
Henrik Zetterberg
Magnus Gisslén
author_facet Jan Jessen Krut
Tomas Mellberg
Richard W Price
Lars Hagberg
Dietmar Fuchs
Lars Rosengren
Staffan Nilsson
Henrik Zetterberg
Magnus Gisslén
author_sort Jan Jessen Krut
collection DOAJ
description Prevalence of neurocognitive impairment in HIV-1 infected patients is reported to be high. Whether this is a result of active HIV-related neurodegeneration is unclear. We examined axonal injury in HIV-1 patients by measuring the light subunit of neurofilament protein (NFL) in CSF with a novel, sensitive method.With a cross-sectional design, CSF concentrations of neurofilament protein light (NFL) (marker of neuronal injury), neopterin (intrathecal immunoactivation) and CSF/Plasma albumin ratio (blood-brain barrier integrity) were analyzed on CSF from 252 HIV-infected patients, subdivided into untreated neuroasymptomatics (n = 200), HIV-associated dementia (HAD) (n = 14) and on combinations antiretroviral treatment (cART) (n = 85), and healthy controls (n = 204). 46 HIV-infected patients were included in both treated and untreated groups, but sampled at different timepoints. Furthermore, 78 neuroasymptomatic patients were analyzed before and after treatment initiation.While HAD patients had the highest NFL concentrations, elevated CSF NFL was also found in 33% of untreated neuroasymptomatic patients, mainly in those with blood CD4+ cell counts below 250 cells/μL. CSF NFL concentrations in the untreated neuroasymptomatics and treated groups were equivalent to controls 18.5 and 3.9 years older, respectively. Neopterin correlated with NFL levels in untreated groups while the albumin ratio correlated with NFL in both untreated and treated groups.Increased CSF NFL indicates ongoing axonal injury in many neuroasymptomatic patients. Treatment decreases NFL, but treated patients retain higher levels than controls, indicating either continued virus-related injury or an aging-like effect of HIV infection. NFL correlates with neopterin and albumin ratio, suggesting an association between axonal injury, neuroinflammation and blood-brain barrier permeability. NFL appears to be a sensitive biomarker of subclinical and clinical brain injury in HIV and warrants further assessment for broader clinical use.
first_indexed 2024-12-23T03:00:36Z
format Article
id doaj.art-028f9393a9b1428ca8e5032546f62b76
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-23T03:00:36Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-028f9393a9b1428ca8e5032546f62b762022-12-21T18:02:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e8859110.1371/journal.pone.0088591Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.Jan Jessen KrutTomas MellbergRichard W PriceLars HagbergDietmar FuchsLars RosengrenStaffan NilssonHenrik ZetterbergMagnus GisslénPrevalence of neurocognitive impairment in HIV-1 infected patients is reported to be high. Whether this is a result of active HIV-related neurodegeneration is unclear. We examined axonal injury in HIV-1 patients by measuring the light subunit of neurofilament protein (NFL) in CSF with a novel, sensitive method.With a cross-sectional design, CSF concentrations of neurofilament protein light (NFL) (marker of neuronal injury), neopterin (intrathecal immunoactivation) and CSF/Plasma albumin ratio (blood-brain barrier integrity) were analyzed on CSF from 252 HIV-infected patients, subdivided into untreated neuroasymptomatics (n = 200), HIV-associated dementia (HAD) (n = 14) and on combinations antiretroviral treatment (cART) (n = 85), and healthy controls (n = 204). 46 HIV-infected patients were included in both treated and untreated groups, but sampled at different timepoints. Furthermore, 78 neuroasymptomatic patients were analyzed before and after treatment initiation.While HAD patients had the highest NFL concentrations, elevated CSF NFL was also found in 33% of untreated neuroasymptomatic patients, mainly in those with blood CD4+ cell counts below 250 cells/μL. CSF NFL concentrations in the untreated neuroasymptomatics and treated groups were equivalent to controls 18.5 and 3.9 years older, respectively. Neopterin correlated with NFL levels in untreated groups while the albumin ratio correlated with NFL in both untreated and treated groups.Increased CSF NFL indicates ongoing axonal injury in many neuroasymptomatic patients. Treatment decreases NFL, but treated patients retain higher levels than controls, indicating either continued virus-related injury or an aging-like effect of HIV infection. NFL correlates with neopterin and albumin ratio, suggesting an association between axonal injury, neuroinflammation and blood-brain barrier permeability. NFL appears to be a sensitive biomarker of subclinical and clinical brain injury in HIV and warrants further assessment for broader clinical use.http://europepmc.org/articles/PMC3921217?pdf=render
spellingShingle Jan Jessen Krut
Tomas Mellberg
Richard W Price
Lars Hagberg
Dietmar Fuchs
Lars Rosengren
Staffan Nilsson
Henrik Zetterberg
Magnus Gisslén
Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
PLoS ONE
title Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
title_full Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
title_fullStr Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
title_full_unstemmed Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
title_short Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
title_sort biomarker evidence of axonal injury in neuroasymptomatic hiv 1 patients
url http://europepmc.org/articles/PMC3921217?pdf=render
work_keys_str_mv AT janjessenkrut biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT tomasmellberg biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT richardwprice biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT larshagberg biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT dietmarfuchs biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT larsrosengren biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT staffannilsson biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT henrikzetterberg biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients
AT magnusgisslen biomarkerevidenceofaxonalinjuryinneuroasymptomatichiv1patients